Jump to content

Search the Community

Showing results for tags 'quality of life'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


    • Announcements, meetings and other resources
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...

Found 7 results

  1. MEN AND SEXUAL HEALTH-PROSTATE CANCER STUDY HOW HAS PROSTATE CANCER AFFECTED YOUR SEX LIFE? WHAT SUPPORT DO YOU NEED? Tell us your story. The Men and Sexual Health-Prostate Cancer study is recruiting men from around the world who have started or received treatment for prostate cancer to take part in a 30 minute online survey. The study examines how prostate cancer affects a man's sense of themselves (masculinity), their sexual concerns after treatment, and overall quality of life. Our ai
  2. Having incurable cancer has caused Larry Axmaker to adjust his definition of "quality of life". Click here to read about how Larry defines "quality of life"
  3. We are all familiar with the concept of intermittent ADT as opposed to continuous ADT. Now researchers are investigating the concept of intermittent chemotherapy as opposed to continuous chemotherapy. If certain criteria are met, there will a break in the chemotherapy treatment and the patient will have a “drug holiday”. In theory intermittent chemotherapy may serve 2 purposes. First, with less constant exposure to the drug, this may potentially delay the development of taxane-refractory disease. Second, breaks in therapy or “drug holidays” ma
  4. At its November meeting the Pharmaceutical Advisory Committee (PBAC) considered an application to extend the listing of enzalutamide (brand name Xtandi) to include treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have not had prior docetaxel (chemotherapy). The PBAC has released its decision on the application. It is what the PBAC describes as a "1st time decision not to recommend". It's disappointing that the application was not successful but encouraging that the PBAC is asking Astellas to resubmit the application. Here is the full de
  5. A good video by the Prostate Cancer Canada Network Calgary. Psychologists from the Tom Baker Cancer Centre in Calgary Canada, Lauren M. Walker and John W. Robinson, share a talk the context of when Androgen Deprivation Therapy, or ADT, is used for treatment. They also talk about the studies and work they've done on the treatment, the side effects and ways to deal with them.
  6. The results of a large, randomized clinical trial of the use of zoledronic acid (Zometa) were presented at the recent annual meeting of the American Society of Clinical Oncology (ASCO). In this trial the researchers set out to test whether giving zoledronic acid every 3 months would be just as effective (i.e., “non-inferior”) at reducing bone pain and skeletal-related events (SREs) in patients with bone metastases as giving it according to the standard recommended regimen (once a month) specified in the product’s prescribing information. They found that zoledronic acid administered eve
  7. The Annual General Meeting of the American Society of Clinical Oncologists (ASCO) is an important event where lots of new developments in oncology are announced and discussed. This year’s meeting will be held from 29 May 2015 to 2 June 2015. Ahead of the meeting, a number of abstracts (summaries of scientific articles) have been released. One of these abstracts was a study by researchers led by Professor Daniel Galvao of Edith Cowan University in Perth. The benefits of exercise for prostate cancer survivors is well established. Professor Galvao and his colleagues studied 463 Au
  • Create New...